{"id":607894,"date":"2022-07-13T18:18:02","date_gmt":"2022-07-13T18:18:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=607894"},"modified":"2022-07-13T18:18:02","modified_gmt":"2022-07-13T18:18:02","slug":"ankylosing-spondylitis-pipeline-therapies-drugs-and-key-pharma-players-involved-by-delveinsight-ucb-inc-abbvie-pfizer-amgenpfizer-janssen-biotech-pozen-novartis-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ankylosing-spondylitis-pipeline-therapies-drugs-and-key-pharma-players-involved-by-delveinsight-ucb-inc-abbvie-pfizer-amgenpfizer-janssen-biotech-pozen-novartis-and-others_607894.html","title":{"rendered":"Ankylosing spondylitis Pipeline Therapies, Drugs and Key pharma players involved by DelveInsight | UCB Inc., AbbVie, Pfizer, Amgen\/Pfizer, Janssen Biotech, Pozen, Novartis and Others."},"content":{"rendered":"
\n
\"Ankylosing<\/a><\/div>\n
\n
Ankylosing spondylitis Pipeline<\/div>\n<\/div>\n<\/div>\n

Ankylosing spondylitis<\/strong> (AS), also called as Bechterev’s disease is a form of arthritis that primarily affects the spine, although other joints may also be involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort. It is a type of axial spondyloarthritis (axSpA) that refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain.<\/p>\n

Ankylosing spondylitis has no known specific cause, though genetic factors seem to be involved. In particular, people who have HLA-B27 gene are at increased risk of developing ankylosing spondylitis.<\/p>\n

On the basis of severity, AS is classified as mild or early AS (stable AS) and severe or advanced AS (active). Early AS usually starts with dull pain in the lower back and the back stiffness, whereas severe AS is associated with continuous inflammation that leads to scarring and permanent damage.<\/p>\n

 <\/p>\n

DelveInsight’s “Ankylosing Spondylitis (Bekhterev’s Disease) Pipeline Insight<\/strong><\/a>” report provides comprehensive insights about 30+ <\/strong>companies and 30+ <\/strong>pipeline drugs in the Ankylosing Spondylitis pipeline landscapes. It comprises Ankylosing Spondylitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ankylosing Spondylitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ankylosing Spondylitis pipeline products.<\/p>\n

 <\/p>\n

Key pharma players involved in <\/strong>Ankylosing spondylitis market<\/strong><\/a> are:<\/strong><\/p>\n

    \n
  1. UCB Inc.<\/li>\n
  2. AbbVie<\/li>\n
  3. Pfizer<\/li>\n
  4. Amgen\/Pfizer<\/li>\n
  5. Janssen Biotech<\/li>\n
  6. Pozen<\/li>\n
  7. Novartis<\/li>\n
  8. Merck<\/li>\n
  9. Horizon Pharma<\/li>\n
  10. Iroko Pharmaceuticals<\/li>\n
  11. And Many More<\/li>\n<\/ol>\n

     <\/p>\n

    Request for free Sample Report: <\/strong>https:\/\/www.delveinsight.com\/report-store\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight<\/strong><\/a><\/p>\n

     <\/p>\n

    Key benefits of the Ankylosing Spondylitis report:<\/strong><\/p>\n